Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 5/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433741 | 0.85 | ALDH1A1 (0.60) | ALDH1A1MAPTKDM4EPOLBLMNA | |
| SCHEMBL1505433 | 0.80 | LMNA (0.48) | ALDH1A1MAPTLMNACDC7DBF4 | |
| SCHEMBL3399807 | 0.76 | CDC7 (0.51) | ALDH1A1MAPTKDM4ELMNACDC7 | |
| SCHEMBL3893108 | 0.75 | ALDH1A1 (0.71) | ALDH1A1KDM4ECDC7DBF4DHODH | |
| SCHEMBL11159408 | 0.75 | MAPT (0.62) | ALDH1A1MAPTKDM4ELMNACDC7 | |
| SCHEMBL2492109 | 0.73 | TRPM8 (0.65) | ALDH1A1MAPTKDM4ECDC7DBF4 | |
| SCHEMBL11281010 | 0.73 | ALDH1A1 (0.55) | ALDH1A1CDC7DBF4DHODHHSD17B10 | |
| SCHEMBL1553106 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MAPTKDM4ELMNACDC7 | |
| SCHEMBL3405221 | 0.73 | LMNA (0.41) | ALDH1A1KDM4EPOLBLMNASMN1; SMN2 | |
| SCHEMBL11279731 | 0.73 | CDC7 (0.69) | ALDH1A1MAPTKDM4ECDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | ALDH1A1 243/4885MAPT 2837/4885KDM4E 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.